Payment overview · 2025
General Payments
$63.30
3 reported records · 2 companies
Healthcare provider profile · identity verified
Stacia Huffman
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NEW MARTINSVILLE, WV · NPI 1871133488
Verified facts
What the public records show
CMS Open Payments records show Stacia Huffman received $63.30 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 78.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.43 | 78.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.87 | 21.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $63.30 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 406 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 78 |
| Lisinopril | Lisinopril | 334 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 73 |
| Gabapentin | Gabapentin | 317 | 51 |
| Losartan Potassium | Losartan Potassium | 310 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 52 |
| Simvastatin | Simvastatin | 207 | 49 |
| Alprazolam | Alprazolam | 199 | 39 |
| Meloxicam | Meloxicam | 190 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 57 |
| Potassium Chloride | Potassium Chloride | 172 | 47 |
| Sertraline Hcl | Sertraline Hcl | 162 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 36 |
| Montelukast Sodium | Montelukast Sodium | 148 | 32 |
| Furosemide | Furosemide | 147 | 41 |
| Metformin Hcl Er | Metformin Hcl | 146 | 41 |
| Famotidine | Famotidine | 139 | 34 |
| Metformin Hcl | Metformin Hcl | 135 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 30 |
| Tramadol Hcl | Tramadol Hcl | 130 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 24 |
| Glipizide | Glipizide | 124 | 29 |
| Trazodone Hcl | Trazodone Hcl | 120 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 28 |
| Eliquis | Apixaban | 111 | 21 |
| Atenolol | Atenolol | 108 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 97 | 21 |
| Ozempic | Semaglutide | 96 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 15 |
| Buspirone Hcl | Buspirone Hcl | 84 | 17 |
| Jardiance | Empagliflozin | 83 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 15 |
| Pregabalin | Pregabalin | 79 | 15 |
| Azithromycin | Azithromycin | 77 | 64 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 26 |
| Clonidine Hcl | Clonidine Hcl | 70 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 15 |
| Ibuprofen | Ibuprofen | 70 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 16 |
| Alendronate Sodium | Alendronate Sodium | 66 | 17 |
| Ezetimibe | Ezetimibe | 65 | 15 |
| Warfarin Sodium | Warfarin Sodium | 64 | 12 |
| Prednisone | Prednisone | 60 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 52 |
| Methocarbamol | Methocarbamol | 59 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 14 |
| Celecoxib | Celecoxib | 55 | 16 |
| Synthroid | Levothyroxine Sodium | 55 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 12 |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 14 |
| Propranolol Hcl | Propranolol Hcl | 49 | 11 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Carvedilol | Carvedilol | 47 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Fluconazole | Fluconazole | 46 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 39 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 38 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 11 |
| Cephalexin | Cephalexin | 34 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 22 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Nystatin | Nystatin | 26 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Dulera | Mometasone/Formoterol | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Elinest | Norgestrel-Ethinyl Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63.30 · 3 records | Novo Nordisk Inc | GVOKE HYPOPEN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error